by University of Helsinki New study reveals that FGFR4 phosphorylates the essential proteins (MST1/2) of Hippo tumor suppressor pathway preventing their activation and induction of programmed cell death in breast cancer cells. Cell death program can be reactivated by blocking FGFR4 function with a speficic inhibitor. These findings suggest new options for eradicating cancer cells...
Tag: <span>cancer cells</span>
Post
Are all cancer cells the same?
Take two cancer cells and compare their genomes. Surprisingly, they can be quite different. This genetic variation is one of the hallmarks of cancer, and one reason why treating cancer is so hard. If a tumour is made up of cells with many different genomes, a single drug might not kill them all. But knowing...
Post
First-in-class DNA-encoded monoclonal antibody therapy rapidly advances into the clinic
The Wistar Institute, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc., announce that the FDA has approved the initiation of a first-in-human clinical trial investigating the safety and tolerability of a novel synthetic DNA-encoded monoclonal antibody (DMAb) therapeutic technology for the prevention of Zika virus infection. DMAb therapeutic technology is unlike all known conventional...
Post
Electric fields: cancer killers?
Pulsing cells with electric fields can force calcium diffusion into cells. Researchers have now optimized this technique in an attempt to kill cancer cells and leave healthy cells intact. Researchers from the Bioelectrics Department of Kumamoto University (Japan) have identified the optimal pulsed electric field (PEF) conditions for the maximum calcium cell membrane permeability. There...
Post
Are there health benefits to taking turmeric?
Can an ancient yellow root spice be good for you? A recent study published in the Proceedings of the National Academy of Sciences shows curcumin, an active ingredient in turmeric, effectively kills certain cancer cells. While research continues on the role turmeric plays in treating cancer, there may be other health benefits to ingesting the...
Post
Bioadhesive, wirelessly-powered implant emitting light to kill cancer cells
Scientists from Waseda University, the National Defense Medical College, and the Japan Science and Technology Agency have developed a new bioadhesive, wirelessly powered light-emitting device that could better treat cancers in delicate organs. The newly-developed, bioadhesive, wirelessly-powered implant. Credit: Dr. Toshinori Fujie, Waseda University Conventional photodynamic therapy induces cancer cell death by using photosensitizing agents,...
Post
Overlooked molecule might be key to how well cancer-fighting CAR-T cells work
Amostly overlooked component of CAR-T cells has a surprisingly strong effect on the cancer-fighting cells’ behavior, scientists reported on Tuesday, including in ways that might affect their safety and efficacy. The component is called the co-stimulatory domain, and the two CAR-T therapies approved last year to treat forms of leukemia and lymphoma — Yescarta and...
Post
To find and disarm: Scientists develop platform to kill cancer cells
NATIONAL UNIVERSITY OF SCIENCE AND TECHNOLOGY MISIS The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and...
Post
CAR-T immunotherapies may have a new player
Emerging CAR-T immunotherapies leverage modified versions of patient’s T-cells to target and kill cancer cells. In a new study, published June 28 online in Cell Stem Cell, researchers at University of California San Diego School of Medicine and University of Minnesota report that similarly modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) also...
Post
Hitchhiking to kill: Transport of lipid-conjugated floxuridine by natural serum albumin for delivery to cancer cells
How can elimination of therapeutics from the bloodstream or their early enzymatic degradation be avoided in systemic delivery? Chinese scientists have new developed a method to bind an established cancer therapeutic, floxuridine, with natural serum albumin for its transport and delivery to target cancer cells. In the journal Angewandte Chemie, the authors demonstrate the automated synthesis...